Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity

References

• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA: A cancer journal for clinicians. 2009;59:225–49.
   PubMed Web of Science ®Google Scholar
• SEER Cancer Statistics Review, 1975–2007. Bethesda, MD: National Cancer Institute; 2010. [cited 27 May 2011]. Available from: http://seer.cancer.gov/csr/1975_2007/.
   Google Scholar
• Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, . Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567–79.
   PubMed Web of Science ®Google Scholar
• Gunderson LL, Haddock MG, Burch P, Nagorney D, Foo ML, Todoroki T. Future role of radiotherapy as a component of treatment in biliopancreatic cancers. Ann Oncol 1999;10(Suppl 4):291–5.
   PubMed Web of Science ®Google Scholar
• Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, . Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial. JAMA 2008;299:1019–26.
   PubMed Web of Science ®Google Scholar
• Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouche O, . Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol 2008;19:1592–9.
   PubMed Web of Science ®Google Scholar
• Loehrer PJ, Sr. Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, . Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: An Eastern Cooperative Oncology Group trial. J Clin Oncol 2011;29:4105–12.
   PubMed Web of Science ®Google Scholar
• Abrams RA. Radiotherapy in the adjuvant management of pancreatic adenocarcinoma. Semin Oncol 2005;32(6 Suppl 9):S30–2.
   Google Scholar
• Koshy MC, Landry JC, Cavanaugh SX, Fuller CD, Willett CG, Abrams RA, . A challenge to the therapeutic nihilism of ESPAC-1. Int J Radiat Oncol Biol Phys 2005;61:965–6.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, . Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomised controlled trial. Lancet 2001;358:1576–85.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, . A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200–10.
   PubMed Web of Science ®Google Scholar
• Yovino S, Poppe M, Jabbour S, David V, Garofalo M, Pandya N, . Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers. Int J Radiat Oncol Biol Phys 2011;79:158–62.
   PubMed Web of Science ®Google Scholar
• Regine WF. Personal Communication. 2010.
   Google Scholar
• Milano MT, Chmura SJ, Garofalo MC, Rash C, Roeske JC, Connell PP, . Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 2004;59:445–53.
   PubMed Web of Science ®Google Scholar
• Abelson JA, Murphy JD, Minn AY, Chung M, Fisher GA, Ford JM, . Intensity-modulated radiotherapy for pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2012;82:e595–601.
   Google Scholar
• Ben-Josef E, Schipper M, Francis IR, Hadley S, Ten-Haken R, Lawrence T, . A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2012;84:1166–71.
   PubMed Web of Science ®Google Scholar
• Hsiung-Stripp DC, McDonough J, Masters HM, Levin WP, Hahn SM, Jones HA, . Comparative treatment planning between proton and X-ray therapy in pancreatic cancer. Med Dosim 2001;26:255–9.
   PubMedGoogle Scholar
• Bouchard M, Amos RA, Briere TM, Beddar S, Crane CH. Dose escalation with proton or photon radiation treatment for pancreatic cancer. Radiother Oncol 2009;92:238–43.
   PubMed Web of Science ®Google Scholar
• Kozak KR, Kachnic LA, Adams J, Crowley EM, Alexander BM, Mamon HJ, . Dosimetric feasibility of hypofractionated proton radiotherapy for neoadjuvant pancreatic cancer treatment. Int J Radiat Oncol Biol Phys 2007;68:1557–66.
   PubMed Web of Science ®Google Scholar
• Hong TS, Ryan DP, Blaszkowsky LS, Mamon HJ, Kwak EL, Mino-Kenudson M, . Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head. Int J Radiat Oncol Biol Phys 2011;79:151–7.
   PubMed Web of Science ®Google Scholar
• Nichols RC, Jr., Huh SN, Prado KL, Yi BY, Sharma NK, Ho MW, . Protons offer reduced normal-tissue exposure for patients receiving postoperative radiotherapy for resected pancreatic head cancer. Int J Radiat Oncol Biol Phys 2012;83:158–63.
   PubMed Web of Science ®Google Scholar
• Terashima K, Demizu Y, Hashimoto N, Jin D, Mima M, Fujii O, . A phase I/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis. Radiother Oncol [Clinical Trial, Phase I Clinical Trial, Phase II] 2012;103:25–31.
   PubMed Web of Science ®Google Scholar
• Huguet F, Goodman KA, Azria D, Racadot S, Abrams RA. Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American-French consensus recommendations. Int J Radiat Oncol Biol Phys 2012;83:1355–64.
   PubMed Web of Science ®Google Scholar